Pegfilgrastim Administered in an Abbreviated Schedule, Significantly Improved Neutrophil Recovery after High-Dose Radiation-Induced Myelosuppression in Rhesus Macaques

Citations Over TimeTop 10% of 2012 papers

Abstract

Conventional daily administration of filgrastim is effective in reducing the duration of severe neutropenia and enhancing survival following lethal radiation, myelosuppressive cytotoxic therapy or myeloablation and stem cell transplantation. A sustained-duration form of filgrastim, pegfilgrastim has significantly simplified scheduling protocols after chemotherapy-induced neutropenia to a single injection while maintaining the therapeutic effectiveness of daily administration of filgrastim. We examined the ability of a single or double (weekly) administration of pegfilgrastim to significantly improve neutrophil recovery in a rhesus macaque model of severe radiation-induced myelosuppression. Animals were exposed to potentially lethal 6 Gy total-body X radiation. After irradiation all animals received supportive care and were administered either pegfilgrastim at 300 μg/kg on day 1 or day 1 and day 7 post exposure, or filgrastim at 10 μg/kg/day initiated on day 1 post exposure and continued daily through neutrophil recovery. Pharmacokinetic parameters and neutrophil-related values for duration of neutropenia, neutrophil nadir, time to recovery to an absolute neutrophil count ≥500/μL or ≥2000/μL, and days of antibiotic support were determined. Effective plasma concentrations of pegfilgrastim were maintained in neutropenic animals until after the onset of hematopoietic recovery, which is consistent with neutrophil-dependent properties of elimination. Administration of pegfilgrastim at day 1 and day 7 was most effective at improving neutrophil recovery compared to daily administration of filgrastim or a single injection of pegfilgrastim on day 1, after severe, radiation-induced myelosuppression in rhesus macaques.

Related Papers

• → Pegfilgrastim Administered in an Abbreviated Schedule, Significantly Improved Neutrophil Recovery after High-Dose Radiation-Induced Myelosuppression in Rhesus Macaques(2012)56 cited
• → Preclinical evaluation of a biobetter candidate: Pharmacokinetics and pharmacodynamics of GX‐G3 in healthy and neutropenia‐induced rats(2019)2 cited
• → Differential Diagnosis of Neutropenia(2001)4 cited
• → GlycoPEGylated Filgrastim XM22 Fixed Dose Demonstrates Similar Activity in Comparison to Pegfilgrastim in Healthy Volunteers after Single Administration.(2007)
• → Study on Effect of Filgrastim in Severe Leukopenia Condition in Dogs(2022)